

TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.

AN 87097896 EMBASE

DN 1987097896

TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.

AU Need A.G.; Chatterton B.E.; Walker C.J.; et al.

CS Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, SA, Australia

SO Maturitas, (1986) 8/4 (275-280).  
CODEN: MATUDK

CY Netherlands

DT Journal

FS 037 Drug Literature Index  
020 Gerontology and Geriatrics  
031 Arthritis and Rheumatism  
030 Pharmacology

LA English

AB Most therapy for osteoporosis has been aimed at decreasing bone resorption and is capable of preventing further bone loss. Recently, anabolic steroids have been claimed to cause increased bone mass in osteoporosis, but the mechanism for this effect is not understood. In this study calcium, and calcium with calcitriol, caused a slowing of forearm bone mineral loss. Calcium and ovarian hormones, with or without calcitriol, caused a small non-significant rise in forearm mineral density, and nandrolone decanoate 50 mg intramuscularly, every 2 or 3 weeks caused a significant rise in forearm mineral density (+15.9  $\pm$  2.4 mg/ml/yr and +13.7  $\pm$  3.4 mg/ml/yr, respectively). The 3-weekly regime caused few side effects and is considered the optimal dose. The striking rise in bone density in patients in whom bone resorption was controlled before therapy, suggests that anabolic steroids can increase the bone formation rate.

RN (calcitriol) 32222-06-3, 32511-63-0, 66772-14-3; (calcium) 7440-70-2; (nandrolone) 434-22-0; (nandrolone decanoate) 360-70-3; (norethisterone) 68-22-4

TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.

AN 82050623 MEDLINE

DN 82050623 PubMed ID: 6795047

TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.

AU Christiansen C; Christensen M S; Rodbro P; Hagen C; Transbol I

SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1981 Aug) 11 (4) 305-9.  
Journal code: 0245331. ISSN: 0014-2972.

CY ENGLAND: United Kingdom

DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals

EM 198201

ED Entered STN: 19900316  
Last Updated on STN: 19900316  
Entered Medline: 19820109

AB Eighty-four normal women, 2.5--5 years after their natural menopause, participated in a controlled double-blind trial. The effect of various therapeutic regimens on postmenopausal bone mineral loss was measured by photonabsorptiometric determination of the bone mineral content of both forearms. The women were randomized into four treatment groups: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo. The groups treated with oestrogens/gestagen (without and with 1,25(OH)2D3) showed a similar increase in bone mineral content of about 1% during one year of treatment. In contrast, both the placebo group and the 1,25(OH)2D3 group demonstrated a decrease of 1.9% and 2.1%, respectively, within the same period of time. While 1,25(OH)2D3 did not alter the rate of bone loss, it caused the characteristic and pronounced increase in urinary calcium excretion (15%). It is concluded that 1,25 (OH)2D3 neither serves as an alternative nor as an additive to gonadal hormones in the prevention of postmenopausal osteoporosis.

RN 32222-06-3 (Calcitriol); 38673-38-0 (norethindrone acetate);  
50-27-1 (Estriol); 50-28-2 (Estradiol); 68-22-4 (Norethindrone);  
7440-70-2 (Calcium)

=> s 32222-06-3/rn  
L1 1 32222-06-3/RN


=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 32222-06-3 REGISTRY  
CN 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta.,5Z,7E)-  
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1,25-Dihydroxycholecalciferol  
CN 1,25-Dihydroxyvitamin D  
CN 1,25-Dihydroxyvitamin D3  
CN 1.alpha.,25-(OH)2D3  
CN 1.alpha.,25-Dihydroxycholecalciferol  
CN 1.alpha.,25-Dihydroxyvitamin D3  
CN Calcijex  
CN Calcitriol  
CN Ro 21-5535  
CN Rocaltrol  
CN Silkis  
CN Solatriol  
CN Topitriol  
CN Toptriol  
FS STEREOSEARCH  
DR 125338-24-1  
MF C27 H44 O3  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT,  
CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,  
DIOGENES, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,  
MRCK\*, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS\*,  
TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9398 REFERENCES IN FILE CA (1947 TO DATE)  
273 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
9408 REFERENCES IN FILE CAPLUS (1947 TO DATE)

=> s norethindrone/cn  
L2 1 NORETHINDRONE/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 68-22-4 REGISTRY  
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)

OTHER NAMES:


CN (17.alpha.)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one  
CN 17-Hydroxy-19-nor-17.alpha.-pregn-4-en-20 yn-3-one  
CN 17.alpha.-Ethinyl-17.beta.-hydroxy-.DELTA.4-estren-3-one  
CN 17.alpha.-Ethinyl-19-nortestosterone  
CN 17.alpha.-Ethinylestr-4-en-17.beta.-ol-3-one  
CN 17.alpha.-Ethinyl-17-hydroxy-4-estrene-3-one  
CN 17.alpha.-Ethinyl-17-hydroxyest-4-en-3-one  
CN 17.alpha.-Ethinyl-17-hydroxyestr-4-en-3-one  
CN 17.alpha.-Ethinyl-17.beta.-hydroxy-19-norandrost-4-en-3-one  
CN 17.alpha.-Ethinyl-17.beta.-hydroxyestr-4-en-3-one  
CN 17.alpha.-Ethinyl-19-nor-androst-4-en-17.beta.-ol-3-one  
CN 17.alpha.-Ethinyl-19-nortestosterone  
CN 17.alpha.-Ethinyl-3-oxo-4-estren-17.beta.-ol  
CN 17.beta.-Hydroxy-17.alpha.-ethinylestr-4-en-3-one  
CN 19-Nor-17.alpha.-ethinyl-17.beta.-hydroxy-4-androsten-3-one  
CN 19-Nor-17.alpha.-ethinylandrosten-17.beta.-ol-3-one  
CN 19-Nor-17.alpha.-ethinyltestosterone  
CN 19-Norandrost-4-en-3-one, 17.alpha.-ethinyl-17.beta.-hydroxy-  
CN 19-Nortestosterone, 17-ethinyl-  
CN Anovule  
CN Conludaf  
CN Conludag  
CN Estr-4-ene-17.alpha.-ethinyl-17.beta.-ol-3-one  
CN Ethinylnortestosterone  
CN Ethinylnortestosterone  
CN Gestest  
CN Menzol  
CN Micronett  
CN Micronor  
CN Micronovum  
CN Mini-Pe  
CN Mini-pill  
CN Nor-QD  
CN Noralutin  
CN Norcolut  
CN **Norethindrone**  
CN Norethisteron  
CN Norethisterone  
CN Norethynodrone  
CN Norfor  
CN Norgestin  
CN Norluten  
CN Norlutin  
CN Norluton  
CN Normapause  
CN Norpregneninolone  
CN NSC 9564  
CN Primolut N  
CN Proluteasi

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

FS STEREOSEARCH

MF C20 H26 O2  
 CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,  
 CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,  
 CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA,  
 MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT,  
 RTECS\*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2149 REFERENCES IN FILE CA (1947 TO DATE)  
 63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 2149 REFERENCES IN FILE CAPLUS (1947 TO DATE)  
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
8.38	8.59

FILE 'CAPLUS' ENTERED AT 06:25:51 ON 23 JUL 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.  
AN 87097896 EMBASE  
DN 1987097896  
TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.  
AU Need A.G.; Chatterton B.E.; Walker C.J.; et al.  
CS Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, SA, Australia  
SO Maturitas, (1986) 8/4 (275-280).  
CODEN: MATUDK  
CY Netherlands  
DT Journal  
FS 037 Drug Literature Index  
020 Gerontology and Geriatrics  
031 Arthritis and Rheumatism  
030 Pharmacology  
LA English  
AB Most therapy for osteoporosis has been aimed at decreasing bone resorption and is capable of preventing further bone loss. Recently, anabolic steroids have been claimed to cause increased bone mass in osteoporosis, but the mechanism for this effect is not understood. In this study calcium, and calcium with calcitriol, caused a slowing of forearm bone mineral loss. Calcium and ovarian hormones, with or without calcitriol, caused a small non-significant rise in forearm mineral density, and nandrolone decanoate 50 mg intramuscularly, every 2 or 3 weeks caused a significant rise in forearm mineral density (+15.9  $\pm$  2.4 mg/ml/yr and +13.7  $\pm$  3.4 mg/ml/yr, respectively). The 3-weekly regime caused few side effects and is considered the optimal dose. The striking rise in bone density in patients in whom bone resorption was controlled before therapy, suggests that anabolic steroids can increase the bone formation rate.  
RN (calcitriol) 32222-06-3, 32511-63-0, 66772-14-3; (calcium) 7440-70-2; (nandrolone) 434-22-0; (nandrolone decanoate) 360-70-3; (norethisterone) 68-22-4

TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.  
AN 82050623 MEDLINE  
DN 82050623 PubMed ID: 6795047  
TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.  
AU Christiansen C; Christensen M S; Rodbro P; Hagen C; Transbol I  
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1981 Aug) 11 (4) 305-9.  
Journal code: 0245331. ISSN: 0014-2972.  
CY ENGLAND: United Kingdom  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Priority Journals  
EM 198201  
ED Entered STN: 19900316  
Last Updated on STN: 19900316  
Entered Medline: 19820109  
AB Eighty-four normal women, 2.5--5 years after their natural menopause, participated in a controlled double-blind trial. The effect of various therapeutic regimens on postmenopausal bone mineral loss was measured by photonabsorptiometric determination of the bone mineral content of both forearms. The women were randomized into four treatment groups: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo. The groups treated with oestrogens/gestagen (without and with 1,25(OH)2D3) showed a similar increase in bone mineral content of about 1% during one year of treatment. In contrast, both the placebo group and the 1,25(OH)2D3 group demonstrated a decrease of 1.9% and 2.1%, respectively, within the same period of time. While 1,25(OH)2D3 did not alter the rate of bone loss, it caused the characteristic and pronounced increase in urinary calcium excretion (15%). It is concluded that 1,25 (OH)2D3 neither serves as an alternative nor as an additive to gonadal hormones in the prevention of postmenopausal osteoporosis.  
RN 32222-06-3 (Calcitriol); 38673-38-0 (norethindrone acetate);  
50-27-1 (Estriol); 50-28-2 (Estradiol); 68-22-4 (Norethindrone);  
7440-70-2 (Calcium)